ReviewClinical drug investigation2022

Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit.

Rieke Alten et al.PubMed ↗Publisher ↗

No numbers read from the abstract.